secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001104659-25-020404
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport reports FY 2024 revenue $228.4M (-2% YoY); guides FY 2025 revenue $240-250M
--------------------------------------------------------------------------------

- FY 2024 revenue $228.4M (down 2% YoY); Q4 revenue $59.5M (up 4% YoY).
- Net loss attributable to common shareholders FY 2024 $122.8M ($2.49/sh) vs $107.6M ($2.21/sh) in FY 2023.
- Commercial Cell & Gene therapy revenue grew 20% YoY to $25.9M in FY 2024.
- Adjusted EBITDA negative $15.1M in FY 2024 vs negative $8.3M in FY 2023.
- FY 2025 revenue guidance $240M-$250M; gross margin improved to 45.8% in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465925020404/0001104659-25-020404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465925020404/tm258273d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-020404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer